Asthma drug trial halted: Dexpramipexole's promise unfulfilled

NCT ID NCT05763121

Disease control Sponsor: Areteia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested dexpramipexole, an oral drug, in over 1,000 people with severe eosinophilic asthma that was not well controlled by standard treatments. The goal was to see if it could reduce severe asthma attacks over a year. However, the study was terminated early, so we do not have clear results on its effectiveness or safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: dexpramipexole
What this could lead to: If successful, this could provide a new oral treatment option to reduce severe asthma attacks in people with eosinophilic asthma.
What could go wrong: The trial was terminated early, so results are limited. It is unclear if dexpramipexole is effective or safe for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,061 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent form and assent form, as appropriate 2. Male or female ≥12 years of age at Screening Visit 1 Asthma-related criteria 3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1. 4. Treatment of asthma, participants must satisfy all the below (items a to c): 1. Participants who have received asthma controller medication with medium or high dose inhaled corticosteroids (ICS; ≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per Global Initiative for Asthma (GINA) 2021) on a regular basis for at least 12 months prior to Screening Visit 1. 2. Documented treatment with a stable dose of either medium or high dose ICS for at least 3 months prior to Screening Visit 1. The ICS may be contained within an ICS/LABA (long-acting β2 agonist) combination product. Daily oral corticosteroids are an allowed concomitant medication; participants on daily oral corticosteroids must be on a stable dose for 3 months before Screening Visit 1. 3. Use of one of more additional daily maintenance asthma controller medications according to standard practice of care is required. Use of a stable dose of any additional asthma controller medications must be documented for at least 3 months prior to Screening Visit 1. 5. Pre-bronchodilator forced expiratory volume (Pre-BD FEV₁) ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2. 6. Variable airflow obstruction documented with at least one of the following criteria: 1. Bronchodilator reversibility at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV₁, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to17). Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening period, at an unscheduled visit at least 7 days prior to baseline. 2. Bronchodilator reversibility, using the criteria above, documented in the past 24 months prior to Screening Visit 1. 3. Peak flow variation of ≥20% over a 2-week period, documented in the past 24 months prior to Screening Visit 1. 4. Airflow variability in clinic FEV₁ ≥20% between two consecutive clinic visits, documented in the past 24 months prior to Screening Visit 1. 5. Airway hyperresponsiveness (provocative concentration causing a 20% fall in FEV₁ of methacholine \<8 mg/mL) documented in the past past 24 months prior to Screening Visit 1. 7. ACQ-6 ≥1.5 at Screening Visit 2. 8. Documented history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period prior to Screening Visit 1. General medical history 9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening Visit 2 and Baseline Visit. 10. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit: 1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive. Or 2. Two protocol acceptable methods of contraception in tandem. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for ≥12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply: 3. Women \<50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range. 4. Women ≥50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. Exclusion Criteria: Asthma-related criteria 1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids) at any time from 4 weeks prior to Screening Visit. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening Visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status. 2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, hypereosinophilic syndrome, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis. 3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1. 4. For participants aged 12 to 17 years old, AEC of \<0.15x10⁹/L at Screening Visit 1. Prohibited medications/procedures 5. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long-acting anti-IL-5) in the past 12 months. 6. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline Visit: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. 7. Treatment with pramipexole (Mirapex®) within 30 days of Baseline Visit. 8. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1. 9. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the coming year. General medical history 10. Weight \<40 kg at Screening Visit 2. 11. Current smoking within the 12 months prior to Screening Visit 1 or a smoking history of \>10 pack-years. Smoking includes tobacco, vaping, and/or marijuana use. 12. Known or suspected alcohol or drug abuse 13. Uncontrolled severe hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg prior to the Baseline Visit despite antihypertensive therapy. 14. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to the Baseline Visit. 15. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C. 16. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1 that has not been treated with or has failed to respond to standard of care (SoC) therapy. 17. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements. 18. Known or suspected noncompliance with medication. 19. Unwillingness or inability to follow the procedures outlined in the protocol. Clinical safety labs 20. Absolute neutrophil count (ANC) \<2.000x10⁹/L at Screening Visit 1 or Screening Visit 2. 21. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula for age ≥18 years at screening; using the Bedside Schwartz eGFR formula). 22. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. Cardiac safety 23. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%. 24. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit. 25. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation. 26. History of long QT syndrome. 27. Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block. 28. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including heart rate \<45 beats per minute (bpm) or \>100 bpm. Pregnancy/Lactation 29. Pregnant women or women breastfeeding 30. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic asthma asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Asthma; eosinophilic Eosinophilic asthma

Contacts and locations

Locations

Researcdh Site 20051-014

Lima, 15046, Peru
Research Site -20054-021

Buenos Aires, B7600FYK, Argentina
Research Site 20001-001

Miami, Florida, 33135, United States
Research Site 20001-002

Kissimmee, Florida, 34746, United States
Research Site 20001-003

West Covina, California, 91790, United States
Research Site 20001-004

Tampa, Florida, 33607, United States
Research Site 20001-005

Brandon, Florida, 33511, United States
Research Site 20001-006

Flint, Michigan, 48504, United States
Research Site 20001-013

Cincinnati, Ohio, 45219, United States
Research Site 20001-014

Green Acres, Florida, 33467, United States
Research Site 20001-015

Kissimmee, Florida, 34744, United States
Research Site 20001-017

Dayton, Ohio, 45424, United States
Research Site 20001-018

Columbus, Georgia, 31904, United States
Research Site 20001-019

Owensboro, Kentucky, 42301, United States
Research Site 20001-020

Homestead, Florida, 33030, United States
Research Site 20001-021

Iowa City, Iowa, 52242, United States
Research Site 20001-023

Dallas, Texas, 75230, United States
Research Site 20001-024

Miami, Florida, 33184, United States
Research Site 20001-025

Greenville, South Carolina, 29615, United States
Research Site 20001-026

Miami, Florida, 33155, United States
Research Site 20001-028

Dallas, Texas, 75235, United States
Research Site 20001-029

Coral Gables, Florida, 33134, United States
Research Site 20001-032

Columbia, South Carolina, 29204, United States
Research Site 20001-034

Cincinnati, Ohio, 45215, United States
Research Site 20001-036

Elwood, Indiana, 46036, United States
Research Site 20001-038

Edmond, Oklahoma, 73034, United States
Research Site 20001-039

Gastonia, North Carolina, 28054, United States
Research Site 20001-043

Newport Beach, California, 92663, United States
Research Site 20001-044

Evansville, Indiana, 47715, United States
Research Site 20001-046

St Louis, Missouri, 63110, United States
Research Site 20001-047

Hawthorne, New York, 10532, United States
Research Site 20001-048

Aventura, Florida, 33180, United States
Research Site 20001-050

East Amherst, New York, 14051, United States
Research Site 20001-051

Brandon, Florida, 33511, United States
Research Site 20001-054

Hialeah, Florida, 33012, United States
Research Site 20001-055

White Marsh, Maryland, 21162, United States
Research Site 20001-057

Madison, Wisconsin, 53792, United States
Research Site 20001-059

Miami, Florida, 33144, United States
Research Site 20001-062

Newport Beach, California, 92660, United States
Research Site 20001-063

Toledo, Ohio, 43617, United States
Research Site 20001-064

Houston, Texas, 77074, United States
Research Site 20001-065

Miami, Florida, 33173, United States
Research Site 20001-066

Miami, Florida, 33126, United States
Research Site 20001-067

Hialeah, Florida, 33016, United States
Research Site 20001-068

Amarillo, Texas, 79124, United States
Research Site 20001-069

St. Petersburg, Florida, 33713, United States
Research Site 20001-072

The Woodlands, Texas, 77380, United States
Research Site 20001-073

Spartanburg, South Carolina, 29303, United States
Research Site 20001-074

Saint Charles, Missouri, 63301, United States
Research Site 20001-075

Augusta, Georgia, 30909, United States
Research Site 20001-079

Oklahoma City, Oklahoma, 73120, United States
Research Site 20001-085

Houston, Texas, 77099, United States
Research Site 20001-086

Loxahatchee Groves, Florida, 33470, United States
Research Site 20001-090

Berwyn, Illinois, 60402, United States
Research Site 20001-135

River Forest, Illinois, 60305, United States
Research Site 20001-148

Flint, Michigan, 48507, United States
Research Site 20001-258

Murray, Utah, 84107, United States
Research Site 20001-340

Burke, Virginia, 22015, United States
Research Site 20001-350

Gainesville, Florida, 32607, United States
Research Site 20001-358

Normal, Illinois, 61761, United States
Research Site 20001-368

The Bronx, New York, 10455, United States
Research Site 20001-370

Chesterfield, Missouri, 63005, United States
Research Site 20001-374

Bakersfield, California, 93301, United States
Research Site 20001-380

Redding, California, 96001, United States
Research Site 20001-382

Raleigh, North Carolina, 27610, United States
Research Site 20001-395

Hershey, Pennsylvania, 17033, United States
Research Site 20001-403

Skokie, Illinois, 60077, United States
Research Site 20001-408

Charlotte, North Carolina, 28273, United States
Research Site 20001-409

Missoula, Montana, 59808, United States
Research Site 20001-419

Westminster, California, 92683, United States
Research Site 20001-420

New Brunswick, New Jersey, 08901, United States
Research Site 20001-422

Rochester, New York, 14607, United States
Research Site 20001-433

La Crosse, Wisconsin, 54601, United States
Research Site 20001-435

Greenville, North Carolina, 27834, United States
Research Site 20001-438

Dickson, Tennessee, 37055, United States
Research Site 20001-440

La Palma, California, 90623, United States
Research Site 20001-456

Takoma Park, Maryland, 20912, United States
Research Site 20001-457

Jersey City, New Jersey, 07304, United States
Research Site 20001-459

Sugar Hill, Georgia, 30518, United States
Research Site 20001-463

Rochester Hills, Michigan, 48307, United States
Research Site 20001-466

Baltimore, Maryland, 21237, United States
Research Site 20001-468

Fall River, Massachusetts, 02723, United States
Research Site 20001-471

Highland Park, New Jersey, 08904, United States
Research Site 20001-473

Las Vegas, Nevada, 89109, United States
Research Site 20001-476

Chicago, Illinois, 60611, United States
Research Site 20001-477

Salt Lake City, Utah, 84107, United States
Research Site 20001-478

Plano, Texas, 75093, United States
Research Site 20001-479

Vienna, Virginia, 22180, United States
Research Site 20001-480

Barboursville, West Virginia, 25504, United States
Research Site 20001-486

Henderson, Nevada, 89052, United States
Research Site 20011-001

Windsor, Ontario, N8X 5A6, Canada
Research Site 20011-004

Ajax, Ontario, LIS 2J5, Canada
Research Site 20011-010

Burlington, Ontario, L7N 3V2, Canada
Research Site 20011-011

Vancouver, British Columbia, V5Z 1M9, Canada
Research Site 20011-016

Ajax, Ontario, L1Z 0M1, Canada
Research Site 20011-018

Montreal, Quebec, H4A 3J1, Canada
Research Site 20011-019

Winnipeg, Manitoba, R2H 2A6, Canada
Research Site 20011-020

Trois-Rivières, Quebec, G9A 4P3, Canada
Research Site 20011-022

Québec, Quebec, G1G 3Y8, Canada
Research Site 20011-024

Guelph, N1H 6J2, Canada
Research Site 20040-002

Brasov, 500051, Romania
Research Site 20040-004

Brasov, Brașov County, 500366, Romania
Research Site 20040-004

Brasov, 500366, Romania
Research Site 20040-006

Cluj-Napoca, Cluj, 400371, Romania
Research Site 20040-008

Bragadiru, 077025, Romania
Research Site 20040-011

Timișoara, 300566, Romania
Research Site 20044-001

Manchester, Greater Manchester, BL9 0NJ, United Kingdom
Research Site 20044-004

Manchester, OL6 6HD, United Kingdom
Research Site 20044-005

Manchester, M27 8HP, United Kingdom
Research Site 20044-008

Salford, Greater Manchester, M6 5WW, United Kingdom
Research Site 20044-009

Manchester, M24 4DZ, United Kingdom
Research Site 20044-010

Altrincham, WA14 1PF, United Kingdom
Research Site 20044-012

Manchester, M42 7WJ, United Kingdom
Research Site 20044-013

Manchester, Greater Manchester, SK8 4NQ, United Kingdom
Research Site 20044-017

Chorley, PR7 7NA, United Kingdom
Research Site 20044-018

Bellshill, ML4 3NJ, United Kingdom
Research Site 20044-019

Liverpool, L22 0LG, United Kingdom
Research Site 20044-020

Manchester, M15 6SE, United Kingdom
Research Site 20044-021

Birmingham, B15 2SQ, United Kingdom
Research Site 20044-022

Enfield, EN3 4GS, United Kingdom
Research Site 20044-024

Preston, PR2 9RB, United Kingdom
Research Site 20044-026

Rochdale, OL11 4AU, United Kingdom
Research Site 20044-029

Stockport, SK3 9NX, United Kingdom
Research Site 20044-030

Manchester, M41 8AA, United Kingdom
Research Site 20044-031

Manchester, M20 6BA, United Kingdom
Research Site 20044-032

Manchester, M23 2SY, United Kingdom
Research Site 20044-033

Manchester, Greater Manchester, M20 2RN, United Kingdom
Research Site 20044-034

Stockport, SK8 5LL, United Kingdom
Research Site 20044-036

London, SE1 7EH, United Kingdom
Research Site 20044-042

London, W12 0HS, United Kingdom
Research Site 20044-046

Manchester, Greater Manchester, M27 0EW, United Kingdom
Research Site 20044-077

Bollington, SK10 5JH, United Kingdom
Research Site 20044-078

Wythenshawe, M23 9QZ, United Kingdom
Research Site 20044-079

Bedford, BD9 6RJ, United Kingdom
Research Site 20044-081

London, EC1M 6BQ, United Kingdom
Research Site 20044-082

Nottingham, NG5 1PB, United Kingdom
Research Site 20044-083

Birmingham, B15 2GW, United Kingdom
Research Site 20044-084

London, E11 EQ, United Kingdom
Research Site 20048-001

Będzin, 42-500, Poland
Research Site 20048-002

Katowice, 40-365, Poland
Research Site 20048-005

Lodz, 50-549, Poland
Research Site 20048-006

Giżycko, 11-500, Poland
Research Site 20048-008

Krakow, 31-159, Poland
Research Site 20048-009

Lodz, 90-302, Poland
Research Site 20048-010

Piaseczno, 05-500, Poland
Research Site 20048-012

Trzebnica, 55-100, Poland
Research Site 20048-014

Skierniewice, 96-100, Poland
Research Site 20048-015

Lodz, 902-141, Poland
Research Site 20048-016

Poznan, 61-578, Poland
Research Site 20048-018

Bialystok, 15-044, Poland
Research Site 20048-019

Wroclaw, 51-162, Poland
Research Site 20048-021

Katowice, 40-081, Poland
Research Site 20048-022

Lublin, 20-289, Poland
Research Site 20048-024

Maków Podhalański, 34-220, Poland
Research Site 20048-027

Krakow, 30-033, Poland
Research Site 20048-028

Poznan, 60-693, Poland
Research Site 20048-029

Wroclaw, 53-301, Poland
Research Site 20048-031

Ostrowiec Świętokrzyski, 27-400, Poland
Research Site 20048-032

Bialystok, 15-430, Poland
Research Site 20048-033

Krakow, 31-011, Poland
Research Site 20048-034

Warsaw, 02-793, Poland
Research Site 20048-036

Kielce, 25-355, Poland
Research Site 20048-037

Torun, Torun 87-100, Poland
Research Site 20048-039

Rzeszów, 35-205, Poland
Research Site 20048-040

Krakow, 31-864, Poland
Research Site 20051-001

Lima, 15131, Peru
Research Site 20051-003

Lima, 15076, Peru
Research Site 20051-006

Lima, 15088, Peru
Research Site 20051-007

Lima, 15082, Peru
Research Site 20051-008

Piura, 20001, Peru
Research Site 20051-009

Lima, 15023, Peru
Research Site 20051-010

Lima, 15102, Peru
Research Site 20051-012

Lima, 15046, Peru
Research Site 20051-013

Lima, 15046, Peru
Research Site 20051-030

Lima, 15073, Peru
Research Site 20052-002

Guadalajara, 44200, Mexico
Research Site 20052-004

Mérida, 97217, Mexico
Research Site 20052-006

Veracruz, 91851, Mexico
Research Site 20052-008

Córdoba, 94550, Mexico
Research Site 20052-009

Zapopan, 45138, Mexico
Research Site 20052-011

Benito Juárez, 03100, Mexico
Research Site 20052-012

San Juan del Río, 76800, Mexico
Research Site 20052-013

Mérida, 97070, Mexico
Research Site 20052-034

Guadalajara, 44950, Mexico
Research Site 20052-035

Cuernavaca, 62250, Mexico
Research Site 20052-037

San Nicolás de los Garza, 66465, Mexico
Research Site 20054-002

San Miguel de Tucumán, T4000CBC, Argentina
Research Site 20054-005

Córdoba, X5003DCE, Argentina
Research Site 20054-008

Buenos Aires, C1426ABP, Argentina
Research Site 20054-010

Mendoza, M5500CCG, Argentina
Research Site 20054-011

Buenos Aires, Bl60IDQD, Argentina
Research Site 20054-013

Rosario, S2000DEJ, Argentina
Research Site 20054-015

Buenos Aires, C1121ABE, Argentina
Research Site 20054-016

Mendoza, M5500CBA, Argentina
Research Site 20054-017

Buenos Aires, C1027AAP, Argentina
Research Site 20054-019

Mendoza, M5500AXR, Argentina
Research Site 20054-020

San Miguel de Tucumán, T4000IAP, Argentina
Research Site 20054-022

Buenos Aires, C1414AIF, Argentina
Research Site 20054-023

Buenos Aires, B7602DCK, Argentina
Research Site 20054-024

Buenos Aires, C1425BEN, Argentina
Research Site 20054-054

Buenos Aires, B1602DQD, Argentina
Research Site 20055-001

São Bernardo do Campo, São Paulo, 09715-590, Brazil
Research Site 20055-002

Sorocaba, São Paulo, 18040-425, Brazil
Research Site 20055-003

São Paulo, 05403, Brazil
Research Site 20055-004

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Research Site 20055-005

Santo André, 09060-870, Brazil
Research Site 20055-007

Blumenau, 89030-101, Brazil
Research Site 20055-008

São Paulo, 09090-790, Brazil
Research Site 20055-009

Santos, São Paulo, 11075-900, Brazil
Research Site 20055-010

Porto Alegre, 91010-006, Brazil
Research Site 20055-011

Campo Largo, 83606, Brazil
Research Site 20055-012

Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
Research Site 20055-014

Ribeirão Preto, São Paulo, 14048-900, Brazil
Research Site 20057-001

Zipaquirá, 250252, Colombia
Research Site 20057-006

Bogotá, 110111, Colombia
Research Site 20057-007

Ibague, 730000001, Colombia
Research Site 20057-008

Barranquilla, 080020, Colombia
Research Site 20057-009

Santander, 681004, Colombia
Research Site 20081-003

Fukuoka, 807-8556, Japan
Research Site 20081-009

Shibuya-ku, 150-8935, Japan
Research Site 20081-011

Yokohama, 236-0004, Japan
Research Site 20081-015

Gifu, 509-6134, Japan
Research Site 20081-016

Yamaguchi, 755-8505, Japan
Research Site 20081-019

Tokyo, 162-8655, Japan
Research Site 20081-021

Nagoya, 454-8509, Japan
Research Site 20081-023

Tokyo, 140-8522, Japan
Research Site 20081-024

Osaka, 560-8552, Japan
Research Site 20081-025

Fukuoka, Japan
Research Site 20081-026

Tokyo, 160-0023, Japan
Research Site 20081-028

Tokyo, 105-8470, Japan
Research Site 20081-029

Tokyo, 204-8585, Japan
Research Site 20081-030

Matsusaka, 515-8544, Japan
Research Site 20081-031

Shizuoka, 420-8527, Japan
Research Site 20081-032

Shimane, 693-8501, Japan
Research Site 20081-034

Tokyo, 104-0031, Japan
Research Site 20081-037

Okayama, 102-3055, Japan
Research Site 20081-038

Toyama, 930-8550, Japan
Research Site 20081-039

Kobe, 653-0013, Japan
Research Site 20081-041

Saga, 849-8501, Japan
Research Site 20081-042

Ibaraki, 319-1113, Japan
Research Site 20081-043

Yoshida, 910-1193, Japan
Research Site 20081-044

Fukuoka, 811-1394, Japan
Research Site 20081-046

Fukuoka, 806-8501, Japan
Research Site 20081-049

Tsuchiura, 300-8585, Japan
Research Site 20081-050

Kagoshima, 890-8520, Japan
Research Site 20081-051

Yokohama, 245-8575, Japan
Research Site 20081-052

Kochi, 783-8509, Japan
Research Site 20081-056

Niigata, 951-8520, Japan
Research Site 20081-061

Shizuoka, 426-8677, Japan
Research Site 20081-062

Toyama, 930-0194, Japan
Research Site 20081-065

Tokyo, 173-8610, Japan
Research Site 20081-066

Tokyo, 160-8582, Japan
Research Site 20081-068

Osaka, 589-8511, Japan
Research Site 20081-069

Isehara, 259-1193, Japan
Research Site 20081-071

Hokkaido, 006-0832, Japan
Research Site 20081-072

Kochi, 783-8505, Japan
Research Site 20081-073

Nagoya, 67-8602, Japan
Research Site 20081-074

Tokyo, 162-8666, Japan
Research Site 20081-076

Saitama, 350-0495, Japan
Research Site 20081-076

Tarumi, 350-0495, Japan
Research Site 20081-077

Himeji, 670-0849, Japan
Research Site 20081-078

Hiroshima, 734-8530, Japan
Research Site 20081-079

Kobe, 650-0017, Japan
Research Site 20081-080

Asahikawa, 078-8510, Japan
Research Site 20081-083

Miura, 238-0111, Japan
Research Site 20081-086

Osaka, 545-8586, Japan
Research Site 20081-087

Yonago, 683-8504, Japan
Research Site 20081-088

Ono, 675-1392, Japan
Research Site 20081-090

Maebashi, 371-8511, Japan
Research Site 20082-003

Anyang, 14068, South Korea
Research Site 20082-004

Seoul, 07061, South Korea
Research Site 20082-006

Jeonju, 54907, South Korea
Research Site 20082-007

Busan, 48108, South Korea
Research Site 20082-008

Seoul, 06591, South Korea
Research Site 20082-009

Daegu, 42415, South Korea
Research Site 20082-010

Suwon, 16499, South Korea
Research Site 20082-011

Seoul, 08308, South Korea
Research Site 20082-013

Seoul, 03080, South Korea
Research Site 20082-014

Seoul, 07345, South Korea
Research Site 20082-019

Seoul, 04763, South Korea
Research Site 20086-001

Taizhou, Zhejang, 318000, China
Research Site 20086-002

Beijing, 101199, China
Research Site 20086-007

Hangzhou, 310014, China
Research Site 20086-009

Nanchang, 330038, China
Research Site 20086-011

Baoding, 07100, China
Research Site 20086-012

Beijing, 100044, China
Research Site 20086-017

Zhejiang, 325000, China
Research Site 20086-019

Qingdao, 266071, China
Research Site 20086-021

Pudong, 201299, China
Research Site 20086-022

Jinan, 250012, China
Research Site 20086-029

Beijing, 102218, China
Research Site 20086-030

Nanchang, 330006, China
Research Site 20086-032

Weifang, 261000, China
Research Site 20086-032

Weifang, China
Research Site 20086-036

Beijing, 100191, China
Research Site 20086-037

Beijing, 100020, China
Research Site 20086-039

Guizhou, 550002, China
Research Site 20086-040

Ningbo, 315040, China
Research Site 20086-041

Shanghai, 200433, China
Research Site 20086-048

Luoyang, 471003, China
Research Site 20086-050

Hangzhou, 310005, China
Research Site 20086-051

Hangzhou, 310006, China
Research Site 20086-052

Shanghai, 200123, China
Research Site 20086-053

Shenyang, 100004, China
Research Site 20086-056

Beijing, 100034, China
Research Site 20086-057

Beijing, 100191, China
Research Site 20086-059

Hangzhou, 310009, China
Research Site 20086-060

Guangdong, 510080, China
Research Site 20086-061

Shanghai, 200032, China
Research Site 20086-063

Shanghai, 200080, China
Research Site 20086-064

Taiyuan, 030001, China
Research Site 20086-066

Wuxi, 214023, China
Research Site 20086-068

Beijing, 100730, China
Research Site 20086-069

Guangzhou, 510140, China
Research Site 20086-071

Jilin City, Jilin, 132011, China
Research Site 20086-072

Guandong, 518020, China
Research Site 20086-075

Guangxi, 541002, China
Research Site 20086-076

Chengdu, 611130, China
Research Site 20359-003

Stara Zagora, 6000, Bulgaria
Research Site 20359-005

Rousse, 7002, Bulgaria
Research Site 20359-006

Sofia, 1510, Bulgaria
Research Site 20359-008

Montana, 3400, Bulgaria
Research Site 20359-009

Sliven, 8800, Bulgaria
Research Site 20359-010

Pernik, 2300, Bulgaria
Research Site 20359-014

Sofia, 1000, Bulgaria
Research Site 20359-015

Sofia, 1612, Bulgaria
Research Site 20359-016

Vidin, 3703, Bulgaria
Research Site 20359-017

Dimitrovgrad, 3703, Bulgaria
Research Site 20359-019

Stara Zagora, 6000, Bulgaria
Research Site 20359-020

Sofia, 1142, Bulgaria
Research Site 20359-021

Velingrad, 4600, Bulgaria
Research Site 20359-022

Kozloduy, 3320, Bulgaria
Research Site 20359-023

Pleven, 5800, Bulgaria
Research Site 20359-024

Plovdiv, 4002, Bulgaria
Research Site 20359-025

Smolyan, 4700, Bulgaria
Research Site 20359-026

Plovdiv, 4000, Bulgaria
Research Site 20359-027

Lovech, 3500, Bulgaria
Research Site 20359-029

Montana, 3400, Bulgaria
Research Site 20359-030

Sofia, 1000, Bulgaria
Research Site 20359-033

Sliven, 8800, Bulgaria
Research Site 20380-001

Ternopil, 46023, Ukraine
Research Site 20380-002

Chernivtsi, 58001, Ukraine
Research Site 20380-003

Vinnytsia, 21001, Ukraine
Research Site 20380-004

Ivano-Frankivsk, 76019, Ukraine
Research Site 20380-005

Zhytomyr, 10002, Ukraine
Research Site 20380-007

Kyiv, 03038, Ukraine
Research Site 20380-008

Vinnytsia, 21029, Ukraine
Research Site 20380-009

Ivano-Frankivsk, 76019, Ukraine
Research Site 20380-010

Kyiv, 03038, Ukraine
Research Site 20380-011

Kyiv, 03115, Ukraine
Research Site 20380-012

Kyiv, 03038, Ukraine
Research Site 20380-013

Kyiv, 03115, Ukraine
Research Site 20380-014

Ivano-Frankivsk, 76019, Ukraine
Research Site 20380-015

Kyiv, 02002, Ukraine
Research Site 20380-016

Lutsk, 45634, Ukraine
Research Site 20380-017

Ivano-Frankivsk, 76008, Ukraine
Research Site 20380-018

Kyiv, 3037, Ukraine
Research Site 20380-019

Kyiv, 02002, Ukraine
Research Site 20380-020

Vinnytsia, 21018, Ukraine
Research Site 20380-021

Chernivtsi, 58022, Ukraine
Research Site 20380-022

Vinnytsia, 21028, Ukraine
Research Site 20381-001

Kragujevac, 3400, Serbia
Research Site 20381-002

Belgrade, 11000, Serbia
Research Site 20381-003

Valjevo, 14000, Serbia
Research Site 20381-004

Niš, 18000, Serbia
Research Site 20381-005

Belgrade, 11080, Serbia
Research Site 20381-006

Belgrade, 11080, Serbia
Research Site 20381-007

Belgrade, 11000, Serbia
Research Site 20381-008

Kamenitz, 21204, Serbia
Research Site 20381-009

Novi Sad, 21000, Serbia
Research Site 20381-009

Incheon, 21565, South Korea
Research Site 20381-010

Belgrade, 11000, Serbia
Research Site 20381-011

Užice, 31000, Serbia
Research Site 20381-012

Belgrade, 11000, Serbia
Research Site 20389-001

Veles, 1400, North Macedonia
Research Site 20389-003

Skopje, 1000, North Macedonia
Research Site 20389-004

Skopje, 1000, North Macedonia
Research Site 20389-005

Strumica, 2400, North Macedonia
Research Site 20389-006

Shtip, 2000, North Macedonia
Research Site 20389-007

Skopje, 1000, North Macedonia
Research Site 20787-365

Guaynabo, 00968, Puerto Rico
Research Site 20787-390

Ponce, 00717, Puerto Rico
Research Site 20961-003

Beirut, Lebanon
Research Site 20961-004

Beirut, Lebanon
Research Site 20961-005

Tripoli, Lebanon
Research Site 20961-007

Aïn Ouzaïn, Lebanon
Research Site 20961-009

Beirut, Lebanon
Research Site 20961-010

Beirut, Lebanon
Research Site 20961-012

Beirut, Lebanon
Research Site 20995-001

Kutaisi, 4600, Georgia
Research Site 20995-002

Tbilisi, 0159, Georgia
Research Site 20995-003

Tbilisi, 0159, Georgia
Research Site 20995-004

Tbilisi, 0159, Georgia
Research Site 20995-005

Tbilisi, 0102, Georgia
Research Site 20995-006

Tbilisi, 0144, Georgia
Research Site 20995-007

Batumi, 6010, Georgia
Research Site 20995-008

Tbilisi, 0186, Georgia
Research Site 20995-009

Tbilisi, 0159, Georgia
Research Site 20995-010

Tbilisi, 0112, Georgia
Research Site US-20001-488

San Diego, California, 92108, United States
Research Site20051-002

Lima, 15131, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.